Kato, R., Ikarashi, D., Matsuura, T., Maekawa, S., Kato, Y., Kanehira, M., . . . Obara, W. (2020). Analyses of Nivolumab Exposure and Clinical Safety Between 3-mg/kg Dosing and 240-mg Flat Dosing in Asian Patients with Advanced Renal Cell Carcinoma in the Real-World Clinical Setting. Transl Oncol.
Citação norma ChicagoKato, Renpei, et al. "Analyses of Nivolumab Exposure and Clinical Safety Between 3-mg/kg Dosing and 240-mg Flat Dosing in Asian Patients With Advanced Renal Cell Carcinoma in the Real-World Clinical Setting." Transl Oncol 2020.
MLA CitationKato, Renpei, et al. "Analyses of Nivolumab Exposure and Clinical Safety Between 3-mg/kg Dosing and 240-mg Flat Dosing in Asian Patients With Advanced Renal Cell Carcinoma in the Real-World Clinical Setting." Transl Oncol 2020.